Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis - Poll - MDSpire

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • By

  • Noppacharn Uaprasert

  • Palada Pitakkitnukun

  • Nuanrat Tangcheewinsirikul

  • Thita Chiasakul

  • Ponlapat Rojnuckarin

  • December 23, 2022

  • 0 min

Share

Original Source(s)

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • by Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, Thita Chiasakul, Ponlapat Rojnuckarin

  • December 23, 2022

Related Content

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis

A Chlamydia trachomatis CPAF-STING agonist conjugate vaccine administered intramuscularly and intradermally is immunogenic in the pig model

The Care Continuum of Patients With Influenza in the Post–COVID-19 Era: A Position Paper